Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kathryn P Gray, Ph.D.

Co-Author

This page shows the publications co-authored by Kathryn Gray and Christopher Sweeney.
Connection Strength

1.993
  1. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer Prostatic Dis. 2021 06; 24(2):341-348.
    View in: PubMed
    Score: 0.223
  2. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019 09; 22(3):420-427.
    View in: PubMed
    Score: 0.199
  3. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019 07; 76(1):89-97.
    View in: PubMed
    Score: 0.198
  4. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2019 09; 2(5):475-482.
    View in: PubMed
    Score: 0.195
  5. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
    View in: PubMed
    Score: 0.191
  6. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016 Dec; 118(6):919-926.
    View in: PubMed
    Score: 0.163
  7. Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol. 2014 Oct; 203(4):W415-20.
    View in: PubMed
    Score: 0.148
  8. Elevated IL-8, TNF-a, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun; 74(8):820-8.
    View in: PubMed
    Score: 0.143
  9. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol. 2014 Feb; 25(2):331-8.
    View in: PubMed
    Score: 0.140
  10. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014 Feb; 74(3):225-34.
    View in: PubMed
    Score: 0.138
  11. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011 Apr; 22(4):801-807.
    View in: PubMed
    Score: 0.112
  12. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
    View in: PubMed
    Score: 0.056
  13. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083.
    View in: PubMed
    Score: 0.045
  14. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene. 2016 09 08; 35(36):4807-15.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.